INSM Insmed Loading...

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
18:48
Sep 20
seedy19tron
Biotech de-grossing, not fundamentals, pressures ABVX
Buy consensus biotech longs $ABVX/$COGT/$INSM, where double-digit drawdowns reflect forced holder de-grossing rather than company fundamentals; a 16.8 RSI on the spread argues against cutting best ideas at these levels.
INSM Insmed Long — —
11:02
Aug 11
seedy19tron
INSM M&A target; respiratory pipeline fits AZN News
Buy INSM as a compelling M&A target for AZN; commercial bronchiectasis launch underway, Arikayce already generating revenue, TPIP entering Phase 3 in PAH — pipeline fits AZN's respiratory franchise and won't get cheaper post-approval.
INSM Insmed Long — —
12:00
Aug 06
seedy19tron
INSM prime AZN acquisition target, respiratory fit News
Buy INSM as a high-probability AZN acquisition target; commercial bronchiectasis launch, Arikayce revenue, and TPIP Phase 3 PAH entry make it a natural bolt-on to AZN's respiratory franchise at a fraction of a BMY deal cost.
INSM Insmed Long 1ST — —
Log in to see ideas

About INSM Investor Commentary

Across the available history and selected sources, Buzzberg tracks INSM (Insmed) across 9 sources: 5 bullish vs 0 bearish calls from 10 authors. Historical directional balance: 14% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 35 total trade ideas tracked. Latest voices: seedy19tron.